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We live in an era in which the pace of research and the obligation to
integrate new discoveries into a ﬁeld’s conceptual framework are
rapidly increasing. At the same time, uncertainties about resources,
funding, positions and promotions, the politics of science, pub-
lishing (the drive to publish in so-called high-impact journals) and
many other concerns are mounting. To consider many of these
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www.molecularmetabolism.comissues critical to conducting research with an emphasis on the
neurobiology of metabolism and related areas. Attendees included a
mix of senior and junior investigators from the United States, Latin
America, and Western Europe, representing several relevant
disciplines.
Participants were initially assigned to small groups to consider
speciﬁc questions in depth, and the results of those deliberations
were then presented and discussed over several plenary sessions.
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Commentaryopinions on some issues, in general there was good consensus
among individuals and the various groups. While the discussions
were wide-ranging, we have condensed the topics into three (albeit
often overlapping) major areas:
1) General research issues applicable to multiple areas of translational
research; for instance, animal models, sex and gender differences,
examples of emerging technologies, as well as the issue of data
reproducibility and related topics.
2) Funding issues, such as how to secure industry funding without
compromising research direction or academic integrity, and the
training of students and fellows, with a focus on how to optimally
prepare trainees for the diverse potential career paths available.
3) Finally, speciﬁc research topics of interest were discussed,
including whether peptides or other signaling compounds, or spe-
ciﬁc brain areas, have “thematic functions” or the challenges
associated with investigating the function of G-protein-coupled
receptors (GPCR) in the brain.
We consider each in turn.2. GENERAL RESEARCH ISSUES
2.1. The selection of animal models
One of the ﬁrst questions considered was how good or bad are our
current experimental models? As might be expected, discussion
initially focused on rats vs. mice. Mice have many obvious advantages
including size, cost per animal, a large genomic database, readily
available genetically modiﬁed strains, and the ability to use smaller
amounts of expensive, hard-to-get experimental compounds. On the
other hand, rats perhaps have more translational value because they
are often better models for human systems and behavior. For instance,
most commonly used laboratory rats (Sprague Dawley, Wistar, Longe
Evans) are outbred strains and hence have considerable genetic
variation, a feature which for many research questions better repre-
sents the genetic heterogeneity and diversity of humans. In addition, in
certain situations such as after gastric bypass surgery, rats may better
model humans because, similar to humans, the substantial reduction
in body weight after gastric bypass surgery is mainly due to a reduction
in food intake. In mice, on the other hand, food intake is often scarcely
changed after gastric bypass surgery, and the reduction in body weight
is largely due to an increase in energy expenditure (for review see [5]).
Rats have also contributed to a large and rich experimental database
and historic development of scientiﬁc theories, especially in behavior,
physiology, and brain structure.
Given technological advances in molecular genetics, it may be that the
‘genetic manipulation’ advantage offered by mice will soon be avail-
able - at least to some extent - for rats and other, larger, mammalian
species that better model certain features of human physiology and
behavior. This is a key factor as many systems remain difﬁcult to
assess at the desired level in rodents. Nevertheless, public concerns
about the use of invasive experimental methods and, in particular,
about performing genetic manipulations in animals larger than labo-
ratory rodents that are phylogenetically closer to humans than mice
and rats may hamper the use of such animal models in science. This
also relates to the question of whether we should always use the best
animal model for a given pathology or whether we should compromise
with a species that is more accepted for ethical reasons and perhaps
even less expensive?
An important concern for much current research is “translationability”
i.e., whether what is found in one species (e.g., rat) is also true of54 MOLECULAR METABOLISM 14 (2018) 53e59  2018 The Authors. Published by Elsevier GmbH. Tanother (e.g., mouse, human). How does this impact or create un-
necessary redundancy on the one hand and reduce the likelihood of
obtaining funding on the other? For example, if one group reports a
phenotype in the mouse, and a researcher using a rat model has the
means to extend the ﬁndings in a novel way, must s/he ﬁrst demon-
strate the basic phenotype in the rat? Many felt that reviewers demand
this intermediate step; i.e., it is widely recognized that there is a
concern for cross-species validation that must be considered. And
while the goal of such research could be justiﬁed as comparative
physiology, the actual goal is often more closely aligned with issues of
modeling and which species more closely resembles human
physiology.
In any case, interfacing well with reviewers (of grant proposals or
manuscripts) requires strong justiﬁcation for any model system. It was
the group’s consensus that the primary scientiﬁc concern should be
the signiﬁcance of the research question being asked. There are no
good or bad models per se, but there are better or worse models for a
particular question, meaning that the value of the model depends on
the nature of the question. There should be well-deﬁned criteria to
justify the choice of any model. In this climate of shrinking extramural
funding, the choice of one model or another must be clearly laid out for
reviewers of research proposals as well as for manuscripts, and
journal editors should pay particular attention to these issues.
For translational research, a possible strategy would be that journals
and funding agencies could include a section detailing the use and
choice of the model and how it relates to human physiology if
appropriate. Due to space constraints, such sections could be included
in the online supplementary material to allow the authors to offer a
detailed explanation of the proposed or used model system, including
its strengths and weaknesses. Such an approach would, over time,
hopefully generate a consensus or at least partial agreement on the
applicability of certain model systems to speciﬁc research questions.
There was considerable discussion about the utility of other experi-
mental models, including dogs, pigs, non-human primates, non-
vertebrates, and computer models. Many of the trade-offs when us-
ing these models are obvious. For example, while non-human primates
can model humans more closely than rodents, costs, ethical, cultural,
and political issues can make such research prohibitive. Differences
among rodent strains are just as likely to be as important as those
between any species (e.g. [3]). For some less common models that can
be justiﬁed for particular questions (for example pigs or other large
animals), a strong case can be made for collaborating with researchers
in animal science, who generally have access to better facilities in
which to conduct such research. On the other hand, for more primitive
animal models, such as zebraﬁsh, C. elegans and other smaller ani-
mals, teaming up with specialists in biology may be a viable option. An
excellent, recent review summarizes the strengths and weaknesses of
currently used animal models [4]. In general, computer models were
deemed to still be somewhat limited for addressing research questions
in whole-animal physiology and behavior. On the other hand, they may
be useful for speciﬁc purposes depending upon what is being
modeled. Examples include computational modeling of molecular
docking and molecular dynamics in drug design to explore the
structure and function of diverse therapeutic targets, or, at the other
end of the spectrum, simulation models of obesity trends with a focus
on the effects of possible policy interventions on public health and
economic outcomes.
The point was made that the use of experimentally modiﬁed genes in
rodent models is now so common that scientiﬁc review groups (e.g., at
NIH) routinely assign much lower priorities to proposals that simply
describe new phenotypes of genetically modiﬁed species. Rather,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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speciﬁc questions regarding gene function need to be addressed
which will beneﬁt from the experimental model of genetic modiﬁcation.
It was noted that industry often takes a different approach to animal
models, where their goal is not necessarily to understand a system but
rather to perform discovery work that leads to marketable drugs or
other products. This aspect of the translation issue is often of ultimate
importance: How do such data predict human responses?
2.2. Sex and gender differences
The impact of certain research directives mandated by the NIH and
other funding agencies, some of which require researchers to design
and conduct experiments in a prescribed manner, was another
continuing theme in many discussions. For example, NIH’s policy
requiring justiﬁcation for using one or both sexes in research raised
several concerns. Some felt that this requirement saps limited re-
sources by “forcing” experiments that are not hypothesis-driven, and
may not generate important and/or relevant ﬁndings.
While investigating sex as a biological variable might be fruitful, it
requires careful experimental design to ensure that the studies are
adequately powered and data analysis is based on a solid knowledge
of genetically- and hormonally-mediated physiological and behavioral
differences between the sexes. Studies in females need to take into
account the 4 stages of the estrus cycle and, as such, can result in the
need for many more animals being studied, including even an
ovariectomized group. Many studies are now including both sexes,
but the experiments are not always designed to reveal potential sex
differences.
Group discussants recognized the value of focused, hypothesis-driven
research on sex differences, and suggestions were offered to improve
the science being conducted while remaining compliant with the
funding mandates. For example, the NIH could provide funding through
which graduate students and postdoctoral fellows could be trained in
labs that specialize in studying sex differences, and thus, know how
such studies should be conducted [e.g., [1,6]]. As sex as a biological
variable is a key part of a recent NIH initiative to enhance reproduc-
ibility through rigor and transparency [see [2]], perhaps NIH could call
for additional proposals that speciﬁcally focus on revealing potential
sex differences. Other suggestions were 1) to have funding agencies
provide supplemental funds for expanding already-funded research to
include both sexes, 2) To focus on critical developmental stages that
might enhance sexual dimorphisms (e.g., puberty, menopause) when
there is likely an important difference, and 3) to fund key exploratory
experiments in a “look see” approach to determine the effect of sex in
established ﬁelds whose ﬁndings are largely based on males. The
overall point is that many researchers now conduct such experiments
in order to be compliant, but they actually have little or no interest in
sex differences per se and no pertinent knowledge.
2.3. Examples of emerging technologies
Many topics were considered, although in depth discussions occurred
for only a few. The following paragraphs reﬂect an extended summary
of one topic that generated particular interest. There was considerable
discussion on the use of designer viruses to deﬁne neural networks
and investigate their functional architecture. A show of hands revealed
that there was widespread use of viruses by the discussants, in part
because they are relatively inexpensive to use, are readily available,
and provide important anatomical speciﬁcity within the nervous sys-
tem. However, there are often strict biohazard regulatory issues
requiring adherence for some viruses.
As with all aspects of research, it is important to know the speciﬁc
question being asked and whether use of a particular virus isMOLECULAR METABOLISM 14 (2018) 53e59  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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divided into two general categories e replication-competent strains
(such as pseudorabies virus which is used for tracing multisynaptic
pathways) and replication-incompetent strains (such as recombinant
adeno-associated virus and lentiviruses expressing cDNAs encoding
light-sensitive channels, calcium sensitive ﬂuorophores or any other
protein or shRNA). Replication-incompetent strains that are broadly
used as expression vectors are generally considered harmless. In both
of these categories, it is essential to consider the biological properties
of the reagent that is to be employed in the experiments and how they
will impact upon the interpretation of the data that are produced. For
example, the virulence of infecting, replication-competent virus strains
has a clear impact upon the speciﬁcity of transport through synaptically
linked populations of neurons as well as the function of infected
neurons within the circuit. The strains of virus most widely used for
circuit analysis have been genetically modiﬁed to reduce virulence
without compromising invasiveness. Nevertheless, these viruses still
evoke an immune response in the nervous system that will ultimately
compromise the function of infected neurons. Thus, temporal analysis
of viral invasiveness of a circuit is an essential component in evaluating
both the organization of the circuit and the function of its constituent
neurons. There was also concern of toxicity of genes that were cloned
into viruses. Fluorescent proteins themselves may generate an im-
mune response and be toxic when overexpressed. Short hairpin RNAs
(shRNA), which are used to silence gene expression, may saturate the
cellular RNAi machinery such that endogenous miRNAs are not pro-
cessed properly, necessitating the use of both scrambled compounds
and non-injected animals as proper controls to interpret the results in
physiological and behavioral experiments, particularly when using
adeno-associated and lentiviruses.
The direction of transport of viruses through a neural circuit is also an
important consideration in experimental design. Well-characterized
strains of viruses have been generated that not only have reduced
virulence but also travel selectively either retrogradely or anterogradely
through a circuit. Many of these reagents are available from individual
investigators as well as through an NIH-funded center headquartered
at the University of Pittsburgh (Center for Neuroanatomy with Neuro-
tropic Viruses or CNNV; http://www.cnnv.pitt.edu). The CNNV also
provides resources to aid in experimental design as well as access to
reviews characterizing the strengths and limitations of the technology.
There was a clear consensus among discussants that it is incumbent
upon the investigator to become informed on the many issues that
impact upon successful application of this demanding technology.
Taking advantage of resources available from investigators expert in
the technology, as well as those available through the CNNV, can help
enormously in achieving that informed perspective.
Increasingly, replication-incompetent viruses and expression vectors
are being combined in individual experiments in order to identify the
connections of functionally deﬁned populations of neurons. These
reagents are mostly employed to highlight connections to a deﬁned
population of neurons or to restrict transport of virus through a single
synapse. Once again, the biological properties of the viruses used and
the ability to alter their genomes are foundational to these powerful
approaches. Alpha herpesviruses (DNA viruses) have been most widely
used to deﬁne the connections of individual populations of neurons
within a larger network, whereas rabies viruses (RNA viruses) are
employed to deﬁne single orders of synaptic input to identiﬁed neu-
rons. In both instances, the ability to alter the viral genome to express
unique reporters of infection, as well as proteins that inﬂuence the
invasion and transport of the reporter viruses, have created the
foundation for the successful development and application of thesecess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 55
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of these approaches highlighted the importance of deﬁning the full
extent of the neurons whose connections are being investigated. For
example, if a neurochemically deﬁned group of neurons is the target of
analysis, do all of those neurons become infected with the virus or the
expression vector? Also essential is to carefully consider the
cytoarchitecture of the injected region and topographical distribution of
the targeted neurons within it. Failure to consider these and other
important issues can lead to unwarranted conclusions regarding the
connectivity of the circuitry under study.
Another approach that is increasingly being applied in the ﬁeld uses
unique ﬂuorescent probes to identify and quantify multiple RNA species
(multiplex analysis) in cell cultures or in tissue sections. The capability
to assay the simultaneous expression of multiple genes in single cells
is very powerful, and several of these methods are currently in use.
However, the fact that some are only available commercially can raise
problems because reagents are expensive and proprietary, meaning
their identity and compositions are not openly available. To offset these
issues collaborative networks among labs have formed to help trou-
bleshoot and circulate alternative approaches among those with
similar interests. As with all mRNA hybridization methods in intact
cells, there are always questions of quantiﬁability and whether or not
one is measuring functional mRNA from which bioactive proteins can
be translated. These uncertainties carry the risk of misinterpreting
data; for example, the temptation to use changing mRNA levels as
proxies of altered protein function.
2.4. The value of replicating published results- the value of failing
to replicate published results
The issue of labs failing to replicate what other labs have reported
generated lively discussion. Discounting instances of fraud or simply
poor training or practice, the discussion settled on ‘good’ science, why
the incidence of failure to replicate is so high (e.g. see [8]), and
possible underlying causes. There is, of course, always something to
learn from differing results because when both sets of experiments are
reliable within one lab or setting, differences between labs likely
indicate that a signiﬁcant, biologically-relevant and as yet unidentiﬁed
variable (e.g., different strains of subject, different food, different
temperature or other lab conditions, etc.) has been overlooked.
Importantly, failures to replicate ﬁndings are relevant for both in vivo
and in vitro research. Hence, problems to replicate are not a reason to
replace in vivo with in vitro experiments, which is an argument often
used by animal protectionists.
At another, perhaps subconscious, level there may be conﬂicts of in-
terest; i.e., there is often pressure to obtain certain data in order to
publish or to secure research funding or a job or promotion, which may
prompt a researcher to be less critical than she/he should be or to
publish data prematurely, i.e., without sufﬁcient replications. Also,
there may be a commercial advantage to promoting one ﬁnding over
another. In some countries, authors receive monetary bonuses for
publishing in high-impact journals (https://www.nature.com/news/
don-t-pay-prizes-for-published-science-1.22275), or one’s salary
may even be directly proportional to one’s publishing record (http://
www.sciencemag.org/news/2017/08/cash-bonuses-peer-reviewed-
papers-go-global). The point is that failure to replicate can be a
complex issue, and we often do not invest sufﬁcient resources in
determining the underlying cause.
An extension of a lack of replication, especially in some ﬁelds, has
been the failure of clinical studies to ﬁnd therapeutic value for drugs
that work quite well in animal models. Although the focus of such
failure is currently to lay the blame on animal models, it should be56 MOLECULAR METABOLISM 14 (2018) 53e59  2018 The Authors. Published by Elsevier GmbH. Tnoted that clinical studies also suffer many shortcomings in experi-
mental design. More germane to the lack of replication is the large
number of fundamental differences that occur in the design and
execution of basic versus clinical studies from statistical handling of
missing or uncertain data to constraints from ethical guidelines.
In practice, the ﬁrst published report of a new ﬁnding or phenomen-
ondparticularly if it is in a high proﬁle journale acquires a certain de
facto power from its originality or novelty. This sets a standard against
which apparently contradictory reports must be judged for publication.
While novelty value is obviously important in science, reports of
apparent failures to replicate, when these occur, may consequently
have to attain a higher bar for publication, even when their methods
are appropriate and rigorous.
Novelty and reproducibility can be reconciled more easily by including
as much detail about the methods as possible. Over time, when several
papers have addressed the same issue, meta-analyses of the pub-
lished data may be useful, but such results often are not conclusive.
Whatever the cause, it is important to include as much methodological
detail as possible in original research reports. But even this can be
difﬁcult given the way that some journals impose space constraints or
relegate methods details to supplementary materials, which are easily
overlooked or disregarded. Some journals (e.g., Journals of the
American Physiological Society, BioMed Central, the British Pharma-
cological Society, the Nature Publishing Group, Physiology and
Behavior, PLOS, and others) request that all animal experiments should
comply with the ARRIVE guidelines (https://www.nc3rs.org.uk/arrive-
guidelines) or the National Institutes of Health Guide for the Care and
Use of Laboratory animals (NIH Publications No. 8023, revised 1978).
Many journals also endorse the completion of a checklist of critical
factors that might affect data validity and robustness (https://www.
nature.com/news/surge-in-support-for-animal-research-guidelines-1.
19274). However, these endorsements alone apparently do not
improve reporting [7], suggesting that the journals should not only
support, but more actively enforce adherence to such good practice in
publishing. One reason for the lack of adherence may be that
complying with these requirements sometimes conﬂicts with the word
or character limit of the manuscript. In any case, adhering to these
guidelines might improve researchers’ ability to parse out methodo-
logical possibilities that underlie differences in results, and it is
desirable that publishers, academic societies and funding agencies will
soon reach consensus. Nevertheless, and perhaps most importantly,
we believe it is our responsibility as scientists to treat each report as a
historical record of what took place in a speciﬁc set of circumstances.
In other words, no single report should be treated as a correct or
incorrect ﬁnding, but rather as a record of history. The point is that a
failure to replicate does not necessarily imply that the initial paper was
incorrect. Rather, the implication is that unknown factors are likely at
play, and that further attempts at replication from other, independent
groups, will be informative.
2.5. Unconscious bias
One perhaps underestimated factor that may contribute to the gen-
eration of irreproducible results is unconscious bias. Everything we do
is subject to unconscious bias, and it is necessary to be aware of this in
order to limit or possibly prevent it. This bias is based on our experi-
ences, culture, prejudices, and many other factors, and it can manifest
when designing experiments or interpreting results as well as when
reviewing manuscripts or grant proposals. It is occasionally reﬂected in
semantics, when scientists unconsciously state that they perform an
experiment to “show something” instead of examining a question or
testing a hypothesis. Unconscious bias is difﬁcult to control, but somehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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guidelines are available (https://royalsociety.org/w/media/policy/
Publications/2015/unconscious-bias-brieﬁng-2015.pdf). The Royal
Society suggests utilizing some key action points to deal with un-
conscious bias: 1) when preparing for a committee meeting or inter-
view, try to slow down the speed of your decision making; 2)
reconsider the reasons for your decision, recognizing that they may be
post-hoc justiﬁcations; 3) question cultural stereotypes that seem
truthful; 4) remember you are unlikely to be fairer and less prejudiced
than the average person; 5) you can detect unconscious bias more
easily in others than in yourself, so be prepared to call out bias when
you see it.
3. FUNDING AND TRAINING ISSUES
3.1. Funding
An important discussion question concerned ways to secure industry
funding without compromising research direction or academic integ-
rity. Several models that are currently working well were discussed.
For example, several companies have formed collaborative funding
foundations within local communities that include a number of aca-
demic research institutions, providing funds to be used for general
areas of interest to them and for which faculty from the various in-
stitutions can apply. Likewise, similar foundations are funded by
groups of philanthropists.
Important issues to consider relate to who owns the data and pub-
lishing rights, what are the indirect costs, and whether or not patents
might arise. The percent of any proﬁts that accrue to the PI or the PI’s
lab differ dramatically among institutions, with examples ranging
from 10 to 90% being given. Can or should graduate students be
recruited to work on industry-funded projects for which proprietary
issues may preclude timely publication? It was clear that different
institutions and investigators take quite different approaches when
addressing these issues.
In addition to contacting a company’s research and development
department, it was suggested that academic researchers seeking
support for early-stage investigations might market their speciﬁc
abilities, techniques, newly minted molecules, or genetically-modiﬁed
mice that could be of special value to the company. Further, re-
searchers might propose to study or utilize a product that the company
is already developing or marketing, in which case prospective funding
may be more forthcoming from the company’s marketing division as
opposed to its R&D branches.
A quick survey of the meeting’s participants indicated that w75%
currently enjoy or have used funds from industry in the past. There was
no apparent opposition to the use of such funds, but it is increasingly
difﬁcult to obtain funding from industry for basic research without
constraints, particularly related to the ability to publish obtained
ﬁndings.
3.2. Training
Pertinent to interactions with private entities, there was discussion of
how doctoral students are being trained. In point of fact, given the
current poor prospects for jobs in academia, many of our PhDs will end
up in non-academic (or non-research) jobs, and a key question is
whether or not we are training them properly for those markets. Ex-
amples of non-traditional career paths taken by newly minted PhDs or
post-docs include positions in administration, law, business, scientiﬁc
writing, teaching, the government, non-governmental organizations,
and many others. It was mentioned that a recent survey by NSF found
that w70% of the current forty thousand or so PhD students in sci-
ences in the US anticipate doing post-docs when they complete theirMOLECULAR METABOLISM 14 (2018) 53e59  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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them to aspire to alternative occupations. It is clear that there are not
that many post-doctoral positions available (especially to newly minted
PhDs), and that, in many cases, post-doctoral training is unnecessary
for the pursuit of alternative non-research-based occupations. As a
result, many PhD students will have to, and should, go into these
alternate career pathways.
Another and perhaps more problematic bottleneck in academic
career paths is ﬁnding a position at the assistant professor level. A
general consensus was that much of the current graduate training is
overly technical and not sufﬁciently conceptual. So, a key question is,
are we training our students appropriately to ensure they are aware
of, and competitive for, the wide variety of potential non-academic
occupations?
Examples of current strategies and policies that might address these
issues include: 1) professional societies or organizations could have
more diverse job fairs or clinics, and more informed position listings on
their websites; 2) universities could offer speciﬁc graduate courses or
seminar series that address alternate careers for scientists; 3) grad-
uate programs could include requirements for grant writing and other
duties of faculty, put students on department committees, and so on,
as these are general skills that are applicable to academic as well as
non-academic jobs; 4) industries could establish more apprenticeship
programs for PhD students with universities if the funding can be
worked out.
One issue that interacts with student training is that, from a mentor’s
point of view, research has to be completed in order to secure funding,
publish papers, advance student careers, and so on. If students are
spending large amounts of time on alternative career building activ-
ities, it can dilute the mentor’s efforts to move projects forward.
Because of this, there is considerable variance among mentors and
their approach to having students acquire broad skills. In any case, one
major goal of a PhD program should be to train the students in “critical
thinking” and to emphasize conceptual training (which will be broadly
applicable to multiple career paths) in addition to technical training. An
interesting possibility is to encourage industrial partners to participate
in teaching activities. This could be leveraged (as currently occurs at
several institutions) by inviting speakers from industry to PhD program
events. Alternatively, it could be beneﬁcial for students to participate in
internal training programs (i.e., the Novartis program in drug discovery)
which would help educate students about the structures and ap-
proaches used in industrial research and development.
4. SPECIFIC RESEARCH TOPICS OF INTEREST
As might be expected, myriad speciﬁc topics were suggested for
discussion, and we therefore highlight a few areas that were broadly
considered.
4.1. “Thematic functions” of peptides, signaling molecules, or
speciﬁc brain areas
There is a historical notion that one or another peptide (or other
compound) which acts at one or more receptors in different systems
and tissues can be considered to have an overall “thematic” or inter-
related function; i.e., the notion that all of its diverse actions can be
related to one over-arching goal (effect) was discussed. Several ex-
amples of such thematic functions do exist. For instance, vasopressin
promotes water retention in the kidney, causes vasoconstriction, and
stimulates water intake by acting in brain, all functions that relate to
available ﬂuid volume in the body and the circulatory system. Oxytocin
(OT) stimulates uterus contractions during birth and myoepithelialcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 57
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promotes emotional bondage as a neuropeptide, functions that can
easily be summarized as being related to reproduction and social
bonding. On the other hand, OT is also involved in descending pro-
jections from the hypothalamus to the hindbrain that modulate satia-
tion signals, a function that cannot directly be related to reproduction or
social bonding. Also, a “thematic” function can hardly be detected for
several other neuropeptides: Neuropeptide Y, for instance, is anabolic,
anxiolytic, and has been implicated in cell proliferation and differen-
tiation. The cocaine and amphetamine-regulated transcript (CART) is
involved in mediation of such diverse functions as pain and eating.
In general, evolutionary pressures likely take advantage of available
compounds for novel functions; e.g., a peptide with one original
function may over time develop novel functions related to that original
“theme” as well as to divergent functions. Over time, this may lead to
new compounds (e.g., ancestral insulin evolved into “modern” insulin
and insulin-like growth factors) or simply apparently unrelated func-
tions of the same compound. Another important point relates to the
anatomical sphere of inﬂuence of the compound. For example,
circulating hormones may be more likely to have a thematic function
because receptors for it in diverse tissues are accessible from the
circulation, whereas a thematic function may be less likely for a
neuropeptide because the release and action of the peptide is conﬁned
to individual, isolated locations.
In short, while the answer to the question of “thematic functions” of
signaling compounds is probably too complex to have been discussed
comprehensively in the available time, there was consensus that a
uniﬁed physiological or “thematic” function is certainly not a universal
principle. Biological systems are considered to have evolved using
whatever ligands and receptors are available to provide important
signaling capacity, and the needs might well differ among systems.
Biological systems are modular, with many interacting parts and levels,
even within a single cell.
Nuclei in the nervous system were originally deﬁned morphologically
rather than functionally, a categorization that still remains the basis
for the majority of standard animal brain atlases. It is clear, however,
that the vast majority of brain nuclei contain diverse cell types that
inﬂuence diverse physiological systems via diverse axonal pro-
jections. Thus, a neuron may synthesize numerous transmitters
(peptides, biogenic amines), with different subsets released at
different terminals or in the same terminal under different conditions
and on a different time scale. As sophisticated techniques became
available, and single cells could be phenotyped, the functional di-
versity of subsets of cells in numerous brain nuclei became apparent.
That said there are also examples of nuclei or portions of nuclei in
which there is a single, dedicated function. Generally, these are nuclei
that are closely allied to sensory or motor functions. For example, this
may be the case for autonomic motor nuclei in the hindbrain or for
some sensory nuclei (e.g., sensory representation of inputs from the
whiskers in the barrel cortex).
4.2. Peptide receptor function
The group discussed challenges associated with investigating the
function of G-protein coupled receptors (GPCR) in the brain. GPCR are
the largest family in the mammalian genome and represent the targets
of many drugs. Therefore, given the relevance of this topic for the
participants, we have included an extended discussion of it here.
GPCR function can easily be misinterpreted. This appears to be an
underappreciated problem that primarily derives from two technical
limitations. First, accurately locating GPCRs within brain cells; and
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leveldis not a trivial task. They are found post-synaptically on den-
drites and neuronal soma and pre-synaptically on axon terminals
where they often reside somewhat distally from the synaptic cleft. For
the most part, GPCR ligands act as modulators rather than mediators of
ionotropic neurotransmission. In addition to occurring on neurons,
GPCRs are also expressed by glial, endothelial, epithelial, and epen-
dymal cells, complicating how experimental manipulations must be
interpreted.
Accurate GPCR localization is hampered by the lack of suitable probes,
particularly high speciﬁcity antibodies. For example, commercially
available GPCR antibodies are often poorly characterized, meaning that
they may provide little useful information. As an alternative, GPCR
location can be addressed by means of what are essentially proxy
approaches. Two are commonly used: 1) appropriate gene promoters
drive the expression of ﬂuorescent markers in target cells; or 2) in situ
hybridization (ISH) is used to locate GPCR encoding mRNAs. While both
techniques have greatly advanced our knowledge about which speciﬁc
cell types express GPCRs, neither provides information about the
precise subcellular location of target GPCRs, nor how altering their
function impacts a neural circuit after a manipulation. For example, it is
not clear how the distribution of a GPCR gene promoter-driven GFP
signal in a neuron relates to the speciﬁc location of the functioning
transmembrane receptor protein; while in-situ-hybridization identiﬁes
mRNA, and not protein. This situation could be dramatically improved
by developing antibodies that are much better targeted to the func-
tionally active epitopes of GPCRs.
With regard to investigating GPCR function, tools are again less than
ideal. Traditional pharmacology offers receptor sub-type speciﬁcity,
but targeted delivery is not always well controlled. An alternative and
ostensibly more targeted approach uses shRNA or other methods to
knock down (KD) receptor gene expression. However, the way that
results from some gene KD experiments appear to be interpreted
raises the possibility that the location of the GPCR affected by the KD is
not always carefully considered. It should be remembered that a
manipulation that reduces the amount of a GPCR mRNA in a target
brain area likely only affects receptor expression in neurons that have
their cell bodies within the area of the injection. This is important
because any presynaptic GPRCs found on afferent neurons projecting
into the target area are unaffected by the KD; these are synthesized by
distally located neuronal populations. The fact that GPCRs can be found
on the axon terminals of target neurons also means that loss of
function is unlikely to be conﬁned just to the region containing its soma
and dendrites. The efferent projections of these neurons will also lose
their pre-synaptic GPCRs, and these may be some distance away.
Interpreting the effects of mRNA KDs is therefore far from straight-
forward, and it is unhelpful that some studies appear to conﬂate the KD
of GPRC mRNAs in neurons within a region with a reduction/loss of all
cognate receptor proteins throughout that region, which probably
doesn’t occur because of presynaptic receptor distribution.
Discussions concluded that the combination of a lack of methods for
accurate localization and of the site-speciﬁc compromise of function
means that current methods still lack the speciﬁcity to address GPRC
function in a sufﬁciently sophisticated manner.
4.3. Redundancy
Why does so much redundancy exist in some biological systems? As
an example, why are there so many peptides and other eating-
generated molecules that act to reduce meal size? The over-
whelming response from the participants was that this is what it takes
for the system to function optimally. While numerous peptides reducehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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food intake as a collective, perhaps redundant, activity, each also has
other unique features. The redundancy for some activities (e.g.,
ingestive behavior) makes the overall metabolic process more efﬁcient
and emphasizes how critical adequate energy is for the two principal
biologic goals e survival and reproduction. For example, whether or
not to eat and how much to eat depend on complex economics
including prey/predator probabilities, the energy it takes to forage and
obtain food, the amount of stored energy on hand, idiosyncratic factors
such as stress or illness, etc. Therefore, the “appropriate” decision is
the result of compromises or balances of competing goals (e.g., to
acquire calories without becoming prey or expending more calories
than are gained in the search for food). There may be a greater inci-
dence of this redundancy in the neural processing of sensory signals or
for life sustaining activities. We see it as a redundancy but it may be an
artifact of our measuring a single variable at a time, using assays and
measurements that have been standardized across laboratories in
order to increase interpretive power. However, these may well miss or
even obscure ﬁner behavior details that are unique to a particular
signaling pathway.
5. PERSPECTIVES/EPILOGUE
As alluded to in the beginning, science at large, as well as research in
our ﬁeld, is currently facing several serious problems: decreases in
funding, bad public opinion/perception of research, questions con-
cerning honesty of the actors, reproducibility and/or relevance of the
data, etc. We as scientists need to be open to justiﬁed criticism from
the outside. In particular, as some of these criticisms raise questions
about the entire “operating system” of science as a whole. It is clear
that doing nothing would be the worst strategy, because it would
further discredit science and eventually result in “punishments” by
funding organizations and the public. Thus, we need to ﬁnd answers to
the questions and solutions to the problems. But what are these an-
swers and solutions? What is the best way forward and how should we
proceed with respect to the various issues where action is needed?
Although the meeting, naturally, did not cover all of the critical issues,
the discussions touched upon a broad range of topics that areMOLECULAR METABOLISM 14 (2018) 53e59  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comimportant for the future of this ﬁeld of research. Reﬂecting on the
combined thoughts and thorough analysis of a large group of excellent
scientists, the results of these discussions may suggest at least some
possible ways to proceed. In this spirit, we hope that this summary of
the major ideas of the meeting may help to promote this important
discussion for our ﬁeld.
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